JP2018501299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501299A5 JP2018501299A5 JP2017543308A JP2017543308A JP2018501299A5 JP 2018501299 A5 JP2018501299 A5 JP 2018501299A5 JP 2017543308 A JP2017543308 A JP 2017543308A JP 2017543308 A JP2017543308 A JP 2017543308A JP 2018501299 A5 JP2018501299 A5 JP 2018501299A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- deuterium
- compound
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 188
- 229910052805 deuterium Inorganic materials 0.000 claims description 187
- 150000001875 compounds Chemical class 0.000 claims description 186
- 239000008194 pharmaceutical composition Substances 0.000 claims description 153
- 150000003839 salts Chemical class 0.000 claims description 142
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 claims description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 52
- 229960003299 ketamine Drugs 0.000 claims description 52
- 208000002193 Pain Diseases 0.000 claims description 43
- 230000002401 inhibitory effect Effects 0.000 claims description 40
- 230000001508 neuroinhibitory effect Effects 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 210000005036 nerve Anatomy 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 239000007916 tablet composition Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 21
- 238000013270 controlled release Methods 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 17
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 230000007135 neurotoxicity Effects 0.000 claims description 7
- 231100000228 neurotoxicity Toxicity 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 208000009205 Tinnitus Diseases 0.000 claims description 5
- 230000008482 dysregulation Effects 0.000 claims description 5
- 229960004502 levodopa Drugs 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 231100000886 tinnitus Toxicity 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 206010010144 Completed suicide Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 5
- 239000007935 oral tablet Substances 0.000 claims 2
- 229940096978 oral tablet Drugs 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 51
- 0 *C(C(*)(*)C(*)=C(*)C1=O)C1(c(c(*)c(*)c(*)c1*)c1Cl)N(*)* Chemical compound *C(C(*)(*)C(*)=C(*)C1=O)C1(c(c(*)c(*)c(*)c1*)c1Cl)N(*)* 0.000 description 14
- 239000006186 oral dosage form Substances 0.000 description 10
- 208000020925 Bipolar disease Diseases 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- 208000021722 neuropathic pain Diseases 0.000 description 7
- 208000008035 Back Pain Diseases 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 6
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000399 orthopedic effect Effects 0.000 description 6
- 239000007894 caplet Substances 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010049714 Abdominal migraine Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010005063 Bladder pain Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 206010070308 Refractory cancer Diseases 0.000 description 3
- 208000008765 Sciatica Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010042458 Suicidal ideation Diseases 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000006197 inhalational dosage form Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNSMPSPTFDIWRQ-GSVOUGTGSA-N (2r)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-GSVOUGTGSA-N 0.000 description 1
- BEQZHFIKTBVCAU-LBPRGKRZSA-N (2s)-2-amino-2-(2-chlorophenyl)cyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(N)CCCCC1=O BEQZHFIKTBVCAU-LBPRGKRZSA-N 0.000 description 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000006137 substance-induced psychosis Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078368A JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074645P | 2014-11-04 | 2014-11-04 | |
| US62/074,645 | 2014-11-04 | ||
| PCT/US2015/059113 WO2016073653A1 (en) | 2014-11-04 | 2015-11-04 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078368A Division JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501299A JP2018501299A (ja) | 2018-01-18 |
| JP2018501299A5 true JP2018501299A5 (https=) | 2018-12-13 |
| JP6882180B2 JP6882180B2 (ja) | 2021-06-02 |
Family
ID=55909773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543308A Active JP6882180B2 (ja) | 2014-11-04 | 2015-11-04 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
| JP2021078368A Pending JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078368A Pending JP2021120389A (ja) | 2014-11-04 | 2021-05-06 | 神経抑制性ケタミンおよびノルケタミン化合物、その誘導体ならびに方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10252982B2 (https=) |
| EP (2) | EP4393487A3 (https=) |
| JP (2) | JP6882180B2 (https=) |
| KR (1) | KR102604397B1 (https=) |
| CN (2) | CN115521217A (https=) |
| AU (1) | AU2015343083B2 (https=) |
| CA (1) | CA2966737A1 (https=) |
| DK (1) | DK3215147T3 (https=) |
| ES (1) | ES2977383T3 (https=) |
| FI (1) | FI3215147T3 (https=) |
| HU (1) | HUE066468T2 (https=) |
| LT (1) | LT3215147T (https=) |
| PL (1) | PL3215147T3 (https=) |
| PT (1) | PT3215147T (https=) |
| RS (1) | RS65411B1 (https=) |
| RU (1) | RU2771275C2 (https=) |
| SI (1) | SI3215147T1 (https=) |
| WO (1) | WO2016073653A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| DK3272338T3 (da) | 2014-04-17 | 2020-11-02 | Develco Pharma Schweiz Ag | Oral doseringsform for ketamin |
| AU2015343083B2 (en) * | 2014-11-04 | 2020-07-23 | Acadia Pharmaceuticals Inc. | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
| WO2016186968A1 (en) * | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| CN110035997A (zh) * | 2016-09-16 | 2019-07-19 | 生物制药沃克斯有限公司 | 羟基去甲氯胺酮前药 |
| US20190240184A1 (en) * | 2016-10-27 | 2019-08-08 | National University Corporation Chiba University | Pharmaceutical applications for (s)-norketamine and salts thereof |
| WO2018191482A2 (en) | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| EP3641742B1 (en) * | 2017-06-23 | 2026-03-25 | Ketabon GmbH | Hydroxynorketamine for the use in the treatment of depression |
| EP3532457B1 (en) | 2017-07-31 | 2020-03-18 | Small Pharma Ltd | Crystalline forms of hydroxynorketamine |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| MX2020003546A (es) | 2017-10-10 | 2020-08-03 | Douglas Pharmaceuticals Ltd | Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| JP2021529732A (ja) | 2018-06-27 | 2021-11-04 | クレキシオ バイオサイエンシーズ エルティーディー． | 大うつ病性障害の処置方法 |
| KR20210074275A (ko) | 2018-10-05 | 2021-06-21 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법 |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| KR20220002905A (ko) * | 2019-03-25 | 2022-01-07 | 더글라스 파머수티클스 리미티드 | 서방형 약학 제제 |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| CN120817937A (zh) * | 2019-08-06 | 2025-10-21 | 加利福尼亚大学董事会 | 聚酮化合物及其制备方法和中间体 |
| CA3155176A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| WO2021137148A1 (en) * | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| MX2022014599A (es) * | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| JP2023543211A (ja) * | 2020-09-24 | 2023-10-13 | ダグラス ファーマシューティカルズ エルティーディー． | 徐放性医薬製剤 |
| CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| JP2024515891A (ja) * | 2021-04-30 | 2024-04-10 | プログレッシブ セラピューティクス インコーポレーテッド | 情緒障害の処置のためのケタミン及びカンナビス |
| CN116730853A (zh) * | 2022-03-04 | 2023-09-12 | 上海致根医药科技有限公司 | 新型氨基酮类化合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| AU2003291037A1 (en) * | 2002-11-18 | 2004-06-15 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
| US20100076087A1 (en) * | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| US8765178B2 (en) * | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| CN101765582A (zh) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| AU2015343083B2 (en) | 2014-11-04 | 2020-07-23 | Acadia Pharmaceuticals Inc. | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
-
2015
- 2015-11-04 AU AU2015343083A patent/AU2015343083B2/en active Active
- 2015-11-04 CN CN202211196697.5A patent/CN115521217A/zh active Pending
- 2015-11-04 HU HUE15856205A patent/HUE066468T2/hu unknown
- 2015-11-04 CA CA2966737A patent/CA2966737A1/en active Pending
- 2015-11-04 ES ES15856205T patent/ES2977383T3/es active Active
- 2015-11-04 CN CN201580072316.4A patent/CN107106529A/zh active Pending
- 2015-11-04 JP JP2017543308A patent/JP6882180B2/ja active Active
- 2015-11-04 US US15/524,224 patent/US10252982B2/en active Active
- 2015-11-04 FI FIEP15856205.8T patent/FI3215147T3/fi active
- 2015-11-04 RS RS20240383A patent/RS65411B1/sr unknown
- 2015-11-04 RU RU2017119222A patent/RU2771275C2/ru active
- 2015-11-04 KR KR1020177015310A patent/KR102604397B1/ko active Active
- 2015-11-04 EP EP24159685.7A patent/EP4393487A3/en active Pending
- 2015-11-04 PL PL15856205.8T patent/PL3215147T3/pl unknown
- 2015-11-04 LT LTEPPCT/US2015/059113T patent/LT3215147T/lt unknown
- 2015-11-04 WO PCT/US2015/059113 patent/WO2016073653A1/en not_active Ceased
- 2015-11-04 DK DK15856205.8T patent/DK3215147T3/da active
- 2015-11-04 SI SI201532004T patent/SI3215147T1/sl unknown
- 2015-11-04 PT PT158562058T patent/PT3215147T/pt unknown
- 2015-11-04 EP EP15856205.8A patent/EP3215147B1/en active Active
-
2019
- 2019-02-08 US US16/271,767 patent/US10981859B2/en active Active
-
2021
- 2021-03-09 US US17/196,986 patent/US11603348B2/en active Active
- 2021-05-06 JP JP2021078368A patent/JP2021120389A/ja active Pending
-
2022
- 2022-08-05 US US17/882,046 patent/US11613515B2/en active Active
-
2023
- 2023-02-14 US US18/168,950 patent/US12466783B2/en active Active
-
2025
- 2025-10-13 US US19/356,894 patent/US20260109663A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501299A5 (https=) | ||
| RU2017119222A (ru) | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения | |
| US20080089861A1 (en) | Combination therapy for treatment of demyelinating conditions | |
| AU2005215775B2 (en) | Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions | |
| CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
| CN101247795B (zh) | 用于治疗与中枢神经系统（cns）相关疾病的方法和组合物 | |
| US20050245460A1 (en) | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders | |
| US20090253728A1 (en) | Methods and Compositions for Treating Nociceptive Pain | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| CN101448502A (zh) | 用于治疗慢性疼痛的特麦角脲/丙麦角脲 | |
| MX2010014223A (es) | Composiciones pediatricas para el tratamiento de esclerosis multiple. | |
| IL292725A (en) | Benzazepines are combined for the treatment of Tourette syndrome | |
| JP2008531594A5 (https=) | ||
| MX2008012729A (es) | Inhibidores de renina para el tratamiento de hipertension. | |
| CN101060830A (zh) | Nmda受体拮抗剂联合抗抑郁症药物单胺氧化酶抑制剂或磷酸甘油醛脱氢酶抑制剂治疗精神疾病 | |
| Chabukswar et al. | A REVIEW ON APPLICATIONS OF DEXMEDETOMIDINE (BXCL501) IN CNS DISORDERS | |
| NZ788970A (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| CN111050800A (zh) | 血清素3受体激动剂对疼痛的治疗 | |
| Fabiano et al. | P. 7. a. 001 Agomelatine efficacy on major sleep disturbances in Smith-Magenis syndrome: an exploratory, open study in children | |
| NZ788970B2 (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| EP0626849A1 (en) | Brofaromine as an agent for treating post-traumatic stress | |
| AU2024204318A1 (en) | Treatment of Post-Traumatic Syndrome Disorder |